Literature DB >> 10878380

Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component.

A J Szalai1, F W van Ginkel, Y Wang, J R McGhee, J E Volanakis.   

Abstract

The acute-phase response (APR) is regulated by TNF-alpha, IL-1beta, and IL-6 acting alone, in combination, or in concert with hormones. The anaphylotoxin C5a, generated during complement activation, induces in vitro the synthesis of these cytokines by leukocytes and of acute-phase proteins by HepG2 cells. However, there is no clear evidence for a role of C5a or any other complement activation product in regulation of the APR in vivo. In this study, using human C-reactive protein (CRP) transgenic mice deficient in C3 or C5, we investigated whether complement activation contributes to induction of the acute-phase proteins CRP and serum amyloid P-component (SAP). Absence of C3 or C5 resulted in decreased LPS-induced up-regulation of the CRP transgene and the mouse SAP gene. Also, LPS induced both the IL-1beta and IL-6 genes in normocomplementemic mice, but in complement-deficient mice it significantly induced only IL-6. Like LPS injection, activation of complement by cobra venom factor led to significant elevation of serum CRP and SAP in normocomplementemic mice but not in complement-deficient mice. Injection of recombinant human C5a into human CRP transgenic mice induced the IL-1beta gene and caused significant elevation of both serum CRP and SAP. However, in human CRP transgenic IL-6-deficient mice, recombinant human C5a did not induce the CRP nor the SAP gene. Based on these data, we conclude that during the APR, C5a generated as a consequence of complement activation acts in concert with IL-6 and/or IL-1beta to promote up-regulation of the CRP and SAP genes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10878380     DOI: 10.4049/jimmunol.165.2.1030

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  C-reactive protein-mediated vascular injury requires complement.

Authors:  Fadi G Hage; Suzanne Oparil; Dongqi Xing; Yiu-Fai Chen; Mark A McCrory; Alexander J Szalai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-03-25       Impact factor: 8.311

2.  Associations between abnormal rod-mediated dark adaptation and health and functioning in older adults with normal macular health.

Authors:  Cynthia Owsley; Carrie Huisingh; Gregory R Jackson; Christine A Curcio; Alexander J Szalai; Nassrin Dashti; Mark Clark; Kia Rookard; Mark A McCrory; Tyler T Wright; Michael A Callahan; Lanning B Kline; C Douglas Witherspoon; Gerald McGwin
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-22       Impact factor: 4.799

Review 3.  Varied biologic functions of C-reactive protein: lessons learned from transgenic mice.

Authors:  Alexander J Szalai; Mark A McCrory
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

4.  Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.

Authors:  G Zandman-Goddard; M Blank; P Langevitz; L Slutsky; M Pras; Y Levy; O Shovman; T Witte; A Doria; J Rovensky; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

Review 5.  C-reactive protein, inflammation, and innate immunity.

Authors:  R F Mortensen
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

6.  Modulation of mouse endotoxic fever by complement.

Authors:  S Li; V M Holers; S A Boackle; C M Blatteis
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

Review 7.  Protective molecules--C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity.

Authors:  Martine Szyper Kravitz; Milena Pitashny; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

8.  Relationship between the tumor necrosis factor alpha polymorphism and the serum C-reactive protein levels in inflammatory bowel disease.

Authors:  Agnes Vatay; László Bene; Agota Kovács; Zoltán Prohászka; Csaba Szalai; László Romics; Béla Fekete; István Karádi; George Füst
Journal:  Immunogenetics       Date:  2003-06-14       Impact factor: 2.846

Review 9.  CRP and the risk of atherosclerotic events.

Authors:  Paolo Calabrò; Enrica Golia; Edward T H Yeh
Journal:  Semin Immunopathol       Date:  2009-05-05       Impact factor: 9.623

10.  Serum C-Reactive Protein (CRP), Target for Therapy or Trouble?

Authors:  Virginia B Kraus; Joanne M Jordan
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.